Beta Bionics, Inc. (BBNX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $10.32 (+1.18%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 18, 2026 | Jonathan Block | Stifel Nicolaus | $22.00 | +113.2% |
| Jan 15, 2026 | David Roman | Goldman Sachs | $25.00 | +142.2% |
| Dec 18, 2025 | Richard Newitter | Truist Financial | $37.00 | +258.5% |
| Oct 29, 2025 | Frank Takkinen | Lake Street | $35.00 | +239.1% |
| Oct 29, 2025 | Jonathan Block | Stifel Nicolaus | $31.00 | +200.4% |
| Oct 29, 2025 | David Roman | Goldman Sachs | $33.00 | +219.8% |
| Oct 29, 2025 | Matt O'Brien | Piper Sandler | $32.00 | +210.1% |
| Oct 29, 2025 | Richard Newitter | Truist Financial | $32.00 | +210.1% |
Top Analysts Covering BBNX
BBNX vs Sector & Market
| Metric | BBNX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.09 | 2.24 | 2.41 |
| Analyst Count | 11 | 8 | 18 |
| Target Upside | +103.5% | +1150.1% | +14.9% |
| P/E Ratio | -6.74 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $132M | $134M | $135M | 8 |
| 2027-03-31 | $37M | $38M | $39M | 4 |
| 2027-06-30 | $41M | $42M | $44M | 3 |
| 2027-09-30 | $46M | $47M | $49M | 3 |
| 2027-12-31 | $52M | $54M | $55M | 3 |
| 2028-03-31 | $50M | $52M | $53M | 2 |
| 2028-06-30 | $56M | $57M | $59M | 5 |
| 2028-09-30 | $59M | $61M | $63M | 4 |
| 2028-12-31 | $66M | $68M | $70M | 4 |
| 2029-12-31 | $290M | $304M | $316M | 7 |
| 2030-12-31 | $363M | $380M | $395M | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.60 | $-2.20 | $-1.65 | 6 |
| 2027-03-31 | $-0.56 | $-0.54 | $-0.51 | 2 |
| 2027-06-30 | $-0.56 | $-0.54 | $-0.52 | 1 |
| 2027-09-30 | $-0.54 | $-0.53 | $-0.50 | 1 |
| 2027-12-31 | $-0.57 | $-0.55 | $-0.52 | 2 |
| 2028-03-31 | $-0.40 | $-0.39 | $-0.37 | 3 |
| 2028-06-30 | $-0.35 | $-0.34 | $-0.33 | 2 |
| 2028-09-30 | $-0.29 | $-0.28 | $-0.27 | 2 |
| 2028-12-31 | $-0.26 | $-0.25 | $-0.24 | 3 |
| 2029-12-31 | $-1.60 | $-1.52 | $-1.43 | 6 |
| 2030-12-31 | $-0.75 | $-0.71 | $-0.67 | 6 |
Frequently Asked Questions
What is the analyst consensus for BBNX?
The consensus among 11 analysts covering Beta Bionics, Inc. (BBNX) is Buy with an average price target of $22.38.
What is the highest price target for BBNX?
The highest price target for BBNX is $37.00, set by Richard Newitter at Truist Financial on 2025-12-18.
What is the lowest price target for BBNX?
The lowest price target for BBNX is $22.00, set by Jonathan Block at Stifel Nicolaus on 2026-02-18.
How many analysts cover BBNX?
11 analysts have issued ratings for Beta Bionics, Inc. in the past 12 months.
Is BBNX a buy or sell right now?
Based on 11 analyst ratings, BBNX has a consensus rating of Buy (2.09/5) with a +103.5% upside to the consensus target of $22.38.
What are the earnings estimates for BBNX?
Analysts estimate BBNX will report EPS of $-2.20 for the period ending 2026-12-31, with revenue estimated at $134M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.